Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
38.58
-0.49 (-1.25%)
Official Closing Price
Updated: 7:00 PM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15,632,499
Open
38.58
Bid (Size)
39.33 (100)
Ask (Size)
39.40 (200)
Prev. Close
39.07
Today's Range
38.16 - 38.85
52wk Range
35.85 - 88.55
Shares Outstanding
N/A
Dividend Yield
3.03%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Can This Next-Gen Obesity Drug Save Novo Nordisk?
↗
Today 10:50 EST
Things can't get that much worse for the drugmaker.
Via
The Motley Fool
Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report
↗
Today 0:07 EST
According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.
Via
Stocktwits
Topics
Initial Public Offering
Intellectual Property
Lawsuit
Performance
YTD
-26.4%
-26.4%
1 Month
-11.0%
-11.0%
3 Month
-17.5%
-17.5%
6 Month
-28.9%
-28.9%
1 Year
-55.7%
-55.7%
More News
Read More
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
↗
March 06, 2026
Via
The Motley Fool
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
↗
March 05, 2026
Via
The Motley Fool
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
March 04, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
Lawsuit
Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again
↗
March 04, 2026
Via
Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
↗
March 03, 2026
Via
The Motley Fool
Topics
Intellectual Property
Unexpected Stock Picks and Looking to the Future
↗
March 02, 2026
Via
The Motley Fool
Why I'm Not Worried About Novo Nordisk Stock
↗
March 02, 2026
Via
The Motley Fool
Topics
Intellectual Property
MarketBeat Week in Review – 02/23 - 02/27
↗
February 28, 2026
Via
MarketBeat
The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
February 27, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
February 27, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
February 27, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
↗
February 27, 2026
Via
The Motley Fool
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
↗
February 26, 2026
Via
The Motley Fool
Why Shares of Novo Nordisk Stock Sank (Again) This Week
↗
February 26, 2026
Via
The Motley Fool
Viking Therapeutics: The High-Stakes Weight Loss Contender
↗
February 26, 2026
Via
MarketBeat
The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier
February 26, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
February 26, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore
↗
February 26, 2026
Via
The Motley Fool
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
↗
February 25, 2026
Via
The Motley Fool
Topics
Stocks
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.
↗
February 25, 2026
Via
The Motley Fool
1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash
↗
February 25, 2026
Via
The Motley Fool
Topics
Economy
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
February 25, 2026
From
Schall Law
Via
GlobeNewswire
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 38.58
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 03/06/26 07:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.